Cargando…
p53 as a unique target of action of cisplatin in acute leukaemia cells
Acute promyelocytic leukaemia (APL) occurs in approximately 10% of acute myeloid leukaemia patients. Arsenic trioxide (ATO) has been for APL chemotherapy, but recently several ATO‐resistant cases have been reported worldwide. Cisplatin (CDDP) enhances the toxicity of ATO in ovarian, lung cancer, chr...
Autores principales: | Kumar, Sanjay, Tchounwou, Paul B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9443951/ https://www.ncbi.nlm.nih.gov/pubmed/35946055 http://dx.doi.org/10.1111/jcmm.17502 |
Ejemplares similares
-
Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells
por: Kumar, Sanjay, et al.
Publicado: (2015) -
Trisenox disrupts MDM2-DAXX-HAUSP complex and activates p53, cell cycle regulation and apoptosis in acute leukemia cells
por: Kumar, Sanjay, et al.
Publicado: (2018) -
Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy
por: Tchounwou, Paul B, et al.
Publicado: (2021) -
Cisplatin-Based Chemotherapy of Human Cancers
por: Brown, Andrea, et al.
Publicado: (2019) -
Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation.
por: Rizzo, M. G., et al.
Publicado: (1998)